• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sangart appoints three to leadership team

Sangart appoints three to leadership team

February 17, 2012
CenterWatch Staff

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

Frank Booth, MA, MSc, BM, BCh, FACS, was appointed to chief medical officer. Booth has more than 20 years of experience as a trauma and critical care surgeon and as a clinical investigator. Previously he worked in clinical development roles at Novo Nordisk and Eli Lilly.

Mary Rose Keller was appointed vice president of clinical operations, responsible for the execution of all clinical programs, including sickle cell, trauma and future treatments at Sangart. She has more than 25 years of experience in clinical research and trial execution and has been involved with numerous, successful regulatory submissions for companies such as Agouron, Pfizer and Shire Pharmaceuticals.

Carmen Betancourt-Riche, MBA, was appointed vice president of regulatory affairs and quality assurance, overseeing the design and execution of Sangart's global regulatory and quality assurance strategy. She more than 34 years of drug development experience in the pharmaceutical industry and has held senior regulatory roles at BioMarin Pharmaceutical, Cerexa, Coulter Pharmaceuticals, Genentech, KaloBios Pharmaceuticals and VaxGen.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing